Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial.

CONCLUSION: In men with castrate levels of E2 and T, daily transdermal E2 0.9-1.8mg increases median serum E2 concentrations into the reference range reported for healthy men, but with substantial variability. E2 treatment reduced hot flushes and bone resorption. Larger studies will be required to test whether low dose E2 treatment can mitigate ADT-associated adverse effects without E2-related toxicity.
PMID: 29549104 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - March 16, 2018 Category: Endocrinology Authors: Russell N, Hoermann R, Cheung AS, Ching M, Zajac J, Handelsman DJ, Grossmann M Tags: Eur J Endocrinol Source Type: research